Canaccord Genuity Research Analyst Matt Bottomley is very focused on the Cannabis sector in both the United States and Canada. But recent moves b y U.S. politicians has him unabashedly excited about Canadian cannabis companies with U.S. operations.
Aphria Inc (TSXV: APH), the Healthcare company, was revisited by a Wall Street analyst today. Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$25.50 price target.
James West: Sure. What would be your favorite Canadian company that has boots on the ground international and is going to get a big chunk of the Canadian market share?
Aphria Inc (TSXV: APH), the Healthcare company, was revisited by a Wall Street analyst today. Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$25.50 price target.
James West: Sure. What would be your favorite Canadian company that has boots on the ground international and is going to get a big chunk of the Canadian market share?
Matt Bottomley: For me, it’s Aphria. The reason for that is it checks all those boxes. I think when you look at the volatility in the market, when you look at the absolute valuation of the top-tier groups, when I say that I mean by infrastructure build, by market capitalization, by current run rates, they really are jockeying for position. By all means, I think Canopy is probably the leader in the space when it comes to its ultimate size and scale and how it’s been able to brand itself already as I think anecdotally when I talk to people entrenched in the industry, everyone knows the Tweed name.
With an Aphria, you’re getting that same exposure at one-third the valuation, and I love the relative valuation on it. I think they probably have the best international exposure with their recent acquisition of Nuuvera. I fully expect, and I don’t know if Ontario’s going to release their purchase orders specifically as Quebec did; where they sort of said here’s our top six and here are the numbers but I fully expect Aphria and the Aphria’s of the world, similar competitors to get very large chunks of those markets too.
James West: Okay, so Aphria is making some pretty aggressive moves with the acquisition of Nuuvera, etc., are there any other Canadian companies are really worthy of paying attention to for the investors that have the potential to make big moves internationally?
Click Here For Full Interview
Click Here For Full Interview
Aphria Inc (TSXV: APH), the Healthcare company, was revisited by a Wall Street analyst today. Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$25.50 price target.
According to TipRanks.com, Bottomley is ranked #261 out of 4778 analysts.
Currently, the analyst consensus on Aphria Inc is Moderate Buy and the average price target is C$25.38, representing a 158.7% upside.
In a report issued on April 24, Clarus also maintained a Buy rating on the stock with a C$25.25 price target.
Aphria, Inc. engages in the production and supply of medical marijuana. Its products include alien dawg, champlian indica, grower’s blend, champlain-sativa and blueberry. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.
Posts
